FR2906724B1 - Methode d'immunisation contre les 4 serotypes de la dengue. - Google Patents

Methode d'immunisation contre les 4 serotypes de la dengue.

Info

Publication number
FR2906724B1
FR2906724B1 FR0608660A FR0608660A FR2906724B1 FR 2906724 B1 FR2906724 B1 FR 2906724B1 FR 0608660 A FR0608660 A FR 0608660A FR 0608660 A FR0608660 A FR 0608660A FR 2906724 B1 FR2906724 B1 FR 2906724B1
Authority
FR
France
Prior art keywords
serotypes
dengue
immunization against
immunization
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
FR0608660A
Other languages
English (en)
French (fr)
Other versions
FR2906724A1 (fr
Inventor
Bruno Guy
Remi Forrat
Jean Lang
Veronique Barban
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Sanofi Pasteur SA
Original Assignee
Sanofi Pasteur SA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sanofi Pasteur SA filed Critical Sanofi Pasteur SA
Priority to FR0608660A priority Critical patent/FR2906724B1/fr
Priority to TW096135167A priority patent/TWI406673B/zh
Priority to TW102119488A priority patent/TW201336508A/zh
Priority to ARP070104316A priority patent/AR063057A1/es
Priority to AU2007311792A priority patent/AU2007311792B2/en
Priority to EP11192672A priority patent/EP2526965A1/fr
Priority to KR1020097008657A priority patent/KR20090064593A/ko
Priority to US11/866,382 priority patent/US7718358B2/en
Priority to EP07858487.7A priority patent/EP2077857B1/fr
Priority to PCT/FR2007/052054 priority patent/WO2008047023A2/fr
Priority to BRPI0719849-3A2A priority patent/BRPI0719849A2/pt
Priority to ZA200901816A priority patent/ZA200901816B/xx
Priority to MX2009003417A priority patent/MX2009003417A/es
Priority to CN2007800444299A priority patent/CN101553251B/zh
Priority to CN201310128837XA priority patent/CN103285386A/zh
Priority to JP2009530916A priority patent/JP5269796B2/ja
Priority to CA002663885A priority patent/CA2663885A1/en
Priority to EP11192665A priority patent/EP2526964A1/fr
Publication of FR2906724A1 publication Critical patent/FR2906724A1/fr
Application granted granted Critical
Publication of FR2906724B1 publication Critical patent/FR2906724B1/fr
Priority to IL197768A priority patent/IL197768A0/en
Priority to US12/718,308 priority patent/US20100270202A1/en
Priority to IL224572A priority patent/IL224572A/en
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5254—Virus avirulent or attenuated
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5256—Virus expressing foreign proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/70—Multivalent vaccine
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/24011—Flaviviridae
    • C12N2770/24111—Flavivirus, e.g. yellow fever virus, dengue, JEV
    • C12N2770/24134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Virology (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Mycology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Microbiology (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
FR0608660A 2006-10-04 2006-10-04 Methode d'immunisation contre les 4 serotypes de la dengue. Expired - Fee Related FR2906724B1 (fr)

Priority Applications (21)

Application Number Priority Date Filing Date Title
FR0608660A FR2906724B1 (fr) 2006-10-04 2006-10-04 Methode d'immunisation contre les 4 serotypes de la dengue.
TW096135167A TWI406673B (zh) 2006-10-04 2007-09-20 對抗４種登革熱血清型之免疫方法
TW102119488A TW201336508A (zh) 2006-10-04 2007-09-20 對抗４種登革熱血清型之免疫方法
ARP070104316A AR063057A1 (es) 2006-10-04 2007-09-28 Metodo de inmunizacion contra los 4 serotipos de dengue
JP2009530916A JP5269796B2 (ja) 2006-10-04 2007-10-02 ４種のデング血清型に対する免疫付与の方法
KR1020097008657A KR20090064593A (ko) 2006-10-04 2007-10-02 4 가지 뎅기열 혈청형에 대한 면역화 방법
US11/866,382 US7718358B2 (en) 2006-10-04 2007-10-02 Method of immunization against the 4 dengue serotypes
EP07858487.7A EP2077857B1 (fr) 2006-10-04 2007-10-02 Methode d'immunisation contre les 4 serotypes de la dengue
PCT/FR2007/052054 WO2008047023A2 (fr) 2006-10-04 2007-10-02 Methode d'immunisation contre les 4 serotypes de la dengue
BRPI0719849-3A2A BRPI0719849A2 (pt) 2006-10-04 2007-10-02 Método de imunização contra os quatro sorotipos da dengue
AU2007311792A AU2007311792B2 (en) 2006-10-04 2007-10-02 Immunisation method against the 4 dengue serotypes
MX2009003417A MX2009003417A (es) 2006-10-04 2007-10-02 Metodo de inmunizacion contra los 4 serotipos de dengue.
CN2007800444299A CN101553251B (zh) 2006-10-04 2007-10-02 针对4种登革热血清型的免疫方法
CN201310128837XA CN103285386A (zh) 2006-10-04 2007-10-02 针对4种登革热血清型的免疫方法
EP11192672A EP2526965A1 (fr) 2006-10-04 2007-10-02 Méthode d'immunisation contre les 4 sérotypes de la Dengue
CA002663885A CA2663885A1 (en) 2006-10-04 2007-10-02 Immunisation method against the 4 dengue serotypes
EP11192665A EP2526964A1 (fr) 2006-10-04 2007-10-02 Méthode d'immunisation contre les 4 sérotypes de la Dengue
ZA200901816A ZA200901816B (en) 2006-10-04 2007-10-02 Immunisation method against the 4 dengue serotypes
IL197768A IL197768A0 (en) 2006-10-04 2009-03-23 Immunisation method against the 4 dengue serotypes
US12/718,308 US20100270202A1 (en) 2006-10-04 2010-03-05 Method of Immunization Against the 4 Dengue Serotypes
IL224572A IL224572A (en) 2006-10-04 2013-02-04 A kit for neutralizing antibodies against the four types of dengue virus

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
FR0608660A FR2906724B1 (fr) 2006-10-04 2006-10-04 Methode d'immunisation contre les 4 serotypes de la dengue.

Publications (2)

Publication Number Publication Date
FR2906724A1 FR2906724A1 (fr) 2008-04-11
FR2906724B1 true FR2906724B1 (fr) 2009-03-20

Family

ID=38222583

Family Applications (1)

Application Number Title Priority Date Filing Date
FR0608660A Expired - Fee Related FR2906724B1 (fr) 2006-10-04 2006-10-04 Methode d'immunisation contre les 4 serotypes de la dengue.

Country Status (15)

Country Link
US (2) US7718358B2 (enExample)
EP (3) EP2077857B1 (enExample)
JP (1) JP5269796B2 (enExample)
KR (1) KR20090064593A (enExample)
CN (2) CN101553251B (enExample)
AR (1) AR063057A1 (enExample)
AU (1) AU2007311792B2 (enExample)
BR (1) BRPI0719849A2 (enExample)
CA (1) CA2663885A1 (enExample)
FR (1) FR2906724B1 (enExample)
IL (2) IL197768A0 (enExample)
MX (1) MX2009003417A (enExample)
TW (2) TWI406673B (enExample)
WO (1) WO2008047023A2 (enExample)
ZA (1) ZA200901816B (enExample)

Families Citing this family (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP5227172B2 (ja) * 2005-08-10 2013-07-03 サノフィ パスツール バイオロジクス リミテッド ライアビリティ カンパニー デングウイルス感染に対するワクチン接種
FR2903605A1 (fr) * 2006-07-12 2008-01-18 Sanofi Pasteur Sa Methode d'immunisation contre les quatres serotypes de la dengue
FR2909286B1 (fr) * 2006-12-01 2012-06-08 Sanofi Pasteur Methode d'immunisation contre les 4 serotypes de la dengue
CN101959527B (zh) 2008-03-05 2016-04-20 赛诺菲巴斯德有限公司 一种使含佐剂的疫苗组合物稳定的方法
EP2143440A1 (fr) * 2008-07-09 2010-01-13 Sanofi Pasteur Agent stabilisant et composition vaccinale comprenant un ou plusieurs flavivirus vivants atténués
AU2010256845B2 (en) * 2009-06-01 2016-09-22 Takeda Vaccines, Inc. Compositions and methods for administration of vaccines against dengue virus
US8968996B2 (en) 2009-06-01 2015-03-03 Takeda Vaccines, Inc. Compositions and methods for rapid immunization against dengue virus
EP2473624B1 (en) 2009-08-31 2019-05-01 Gen-Probe Incorporated Dengue virus assay
EP2353609A1 (en) * 2010-02-04 2011-08-10 Sanofi Pasteur Immunization compositions and methods
WO2011119628A2 (en) 2010-03-23 2011-09-29 The Regents Of The University Of California Compositions and methods for self-adjuvanting vaccines against microbes and tumors
BR112013032421A2 (pt) * 2011-06-29 2017-01-17 Immunotope Inc método para profilaxia ou tratamento de uma infecção pelo vírus da dengue, método para induzir uma resposta imune mediada por linfócito t citotóxico, vacina contra o vírus da dengue, método para prevenir uma doença causada pelo vírus da dengue e método para induzir uma resposta imune a pelo menos um vírus da dengue
JP2015520196A (ja) * 2012-06-10 2015-07-16 タケダ ワクチン, インコーポレイテッドTakeda Vaccines, Inc. デングウイルスに対するワクチン投与のための組成物および方法
US8895028B2 (en) * 2012-07-20 2014-11-25 Arbovax, Inc. Methods and compositions for dengue virus 3 (DV3) infectious clone
SG10201912291YA (en) * 2012-07-24 2020-02-27 Sanofi Pasteur Vaccine compositions
AU2013295016A1 (en) 2012-07-24 2015-01-29 Sanofi Pasteur Vaccine compositions for prevention against dengue virus infection
BR112015012515B1 (pt) 2012-11-30 2023-04-11 Sanofi Pasteur Uso de antígenos, construções de ácido nucleico ou vetores virais capazes de expressar uma partícula do tipo vírus (vlp) da dengue e de uma vacina contra sarampo, uma vacina contra caxumba e uma vacina contra rubéola
US9878031B2 (en) 2012-12-14 2018-01-30 Takeda Vaccines, Inc. Compositions, methods of administration and uses for trivalent dengue virus formulations
JP2016523251A (ja) 2013-06-21 2016-08-08 メルク・シャープ・アンド・ドーム・コーポレーションＭｅｒｃｋ Ｓｈａｒｐ ＆ Ｄｏｈｍｅ Ｃｏｒｐ． デングウイルスワクチン組成物およびその使用方法
TWI852899B (zh) * 2014-09-02 2024-08-21 法商賽諾菲巴斯德公司 疫苗組合物
ES2981476T3 (es) 2014-12-22 2024-10-09 Merck Sharp & Dohme Llc Composiciones de vacunas contra el virus del dengue y métodos de uso de las mismas
EP3316905A1 (en) 2015-07-03 2018-05-09 Sanofi Pasteur Concomitant dengue and yellow fever vaccination
KR102373570B1 (ko) * 2015-11-27 2022-03-10 케이엠 바이올로직스 가부시키가이샤 뎅기 바이러스 약독주를 뱅크화한 생바이러스, 및 그것들을 항원으로 하는 뎅기 백신
WO2019069130A1 (en) 2017-10-05 2019-04-11 Sanofi Pasteur COMPOSITIONS FOR RECALL VACCINATION AGAINST DENGUE
EP3846849A1 (en) 2018-09-05 2021-07-14 Takeda Vaccines, Inc. Dengue vaccine unit dose and administration thereof
BR112022001476A2 (pt) 2019-08-16 2023-10-03 Takeda Vaccines Inc Uso de uma vacina contra hepatite a e uma composição de vacina contra dengue ou uma dose unitária de uma composição de vacina contra dengue, combinação de vacina e kit
BR112022015710A2 (pt) 2020-02-27 2022-09-27 Takeda Vaccines Inc Método para remover dna de célula hospedeira a partir da preparação de vírus
WO2023147342A2 (en) 2022-01-25 2023-08-03 Takeda Vaccines, Inc. Large-scale flaviviral vaccine production and manufacture
US20250177511A1 (en) 2022-02-15 2025-06-05 Takeda Vaccines, Inc. Dengue vaccine batch mixing process
US20250342705A1 (en) 2022-05-04 2025-11-06 Takeda Vaccines, Inc. Computer-based determination of flavivirus infectivity
WO2024108087A1 (en) 2022-11-18 2024-05-23 Takeda Vaccines, Inc. A method for determining the proportion of a live, attenuated flavivirus having a nucleotide sequence comprising at least one attenuation locus in a formulation
EP4626574A1 (en) 2022-11-29 2025-10-08 Takeda Vaccines, Inc. Large-scale flaviviral vaccine production and manufacture
WO2025072259A1 (en) 2023-09-25 2025-04-03 Takeda Vaccines, Inc. Coadministration of tetravalent dengue vaccine with hpv vaccine
WO2025122855A1 (en) 2023-12-08 2025-06-12 Takeda Vaccines, Inc. A method for determining the concentration of residual vero cell genomic dna in a sample containing virus obtained from production in vero cells

Family Cites Families (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1996040933A1 (en) 1995-06-07 1996-12-19 The Government Of The United States Of America, Represented By The Secretary Department Of Health And Human Services Infectious dengue 2 virus pdk-53 as quadravalent vaccine
EP0977587B1 (en) 1997-02-28 2005-06-15 Acambis Inc. Chimeric flavivirus vaccines
EP1080370A4 (en) 1998-05-29 2003-07-30 Epimmune Inc IDENTIFICATION OF RESILIENT DR EPITOPES LARGELY REACTIVE
EP1165127B1 (en) * 1999-03-26 2008-12-31 Walter Reed Army Institute of Research Multivalent dengue virus vaccine
US6537557B1 (en) * 1999-03-26 2003-03-25 The United States Of America As Represented By The Secretary Of The Army Attenuated dengue-4 virus vaccine
CA2368790A1 (en) 1999-03-26 2000-10-05 Walter Reed Army Institute Of Research Attenuated dengue-3 virus vaccine
JP2002540169A (ja) 1999-03-26 2002-11-26 ウォルター リード アーミー インスティテュート オブ リサーチ 弱毒化デング熱１型ウイルスワクチン
WO2000057909A2 (en) 1999-03-26 2000-10-05 Walter Reed Army Institute Of Research Attenuated dengue-2 virus vaccine
US6632663B1 (en) 1999-09-22 2003-10-14 Aventis Pasteur Limited DNA immunization against chlamydia infection
ATE526411T1 (de) 2000-02-16 2011-10-15 Us Gov Health & Human Serv Avirulente, immunogene flavivirus-chimäre
EP1159969A1 (fr) 2000-05-30 2001-12-05 Aventis Pasteur Vaccine composition
ATE412738T1 (de) * 2000-05-30 2008-11-15 Univ Mahidol Attenuierte stammen von denguevirus und ihre verwendungen in impfstoffzusammensetzungen
AT410634B (de) 2001-02-21 2003-06-25 Franz X Dr Heinz Attenuierte lebendimpfstoffe
CA2966716C (en) 2001-05-22 2019-11-26 The Government Of The United States Of America, As Represented By The Cretary, Department Of Health And Human Services Development of mutations useful for attenuating dengue viruses and chimeric dengue viruses
WO2002095007A2 (en) 2001-05-23 2002-11-28 Dendreon San Diego Llc Conjugates activated by cell surface proteases and therapeutic uses thereof
CN1551782A (zh) 2001-06-01 2004-12-01 ��������ķ������ 嵌合黄病毒载体
US20040120964A1 (en) * 2001-10-29 2004-06-24 Mikszta John A. Needleless vaccination using chimeric yellow fever vaccine-vectored vaccines against heterologous flaviviruses
KR101074175B1 (ko) * 2002-01-15 2011-10-14 사노피 파스테르 바이오로직스 씨오 플라비바이러스 백신
US20040259224A1 (en) * 2002-05-31 2004-12-23 Farshad Guirakhoo Tetravalent Dengue vaccines
ES2345200T3 (es) 2003-03-24 2010-09-17 The Scripps Research Institute Vacunas de adn contra el crecimiento tumoral y procedimientos de utilizacion de las mismas.
CN101238144B (zh) * 2005-06-17 2012-09-05 赛诺菲巴斯德有限公司 登革血清型1减毒株
JP5227172B2 (ja) * 2005-08-10 2013-07-03 サノフィ パスツール バイオロジクス リミテッド ライアビリティ カンパニー デングウイルス感染に対するワクチン接種
FR2903605A1 (fr) * 2006-07-12 2008-01-18 Sanofi Pasteur Sa Methode d'immunisation contre les quatres serotypes de la dengue
FR2909286B1 (fr) 2006-12-01 2012-06-08 Sanofi Pasteur Methode d'immunisation contre les 4 serotypes de la dengue

Also Published As

Publication number Publication date
TWI406673B (zh) 2013-09-01
US7718358B2 (en) 2010-05-18
CN101553251A (zh) 2009-10-07
AR063057A1 (es) 2008-12-23
IL224572A (en) 2014-06-30
US20080085288A1 (en) 2008-04-10
IL197768A0 (en) 2011-08-01
AU2007311792B2 (en) 2013-05-02
CA2663885A1 (en) 2008-04-24
MX2009003417A (es) 2009-04-09
EP2526965A1 (fr) 2012-11-28
CN101553251B (zh) 2013-05-22
WO2008047023A3 (fr) 2008-10-23
JP5269796B2 (ja) 2013-08-21
EP2077857B1 (fr) 2013-11-20
ZA200901816B (en) 2010-06-30
BRPI0719849A2 (pt) 2014-04-29
KR20090064593A (ko) 2009-06-19
AU2007311792A1 (en) 2008-04-24
TW201336508A (zh) 2013-09-16
FR2906724A1 (fr) 2008-04-11
EP2077857A2 (fr) 2009-07-15
EP2526964A1 (fr) 2012-11-28
JP2010505801A (ja) 2010-02-25
TW200826959A (en) 2008-07-01
CN103285386A (zh) 2013-09-11
WO2008047023A2 (fr) 2008-04-24
US20100270202A1 (en) 2010-10-28

Similar Documents

Publication Publication Date Title
FR2906724B1 (fr) Methode d'immunisation contre les 4 serotypes de la dengue.
FR2909286B1 (fr) Methode d'immunisation contre les 4 serotypes de la dengue
ZA200900155B (en) Method of immunisation against the four serotypes of dengue
IL284991A (en) Antibodies against cd38 for treatment of multiple myeloma
EP2318530A4 (en) NEW EPITOP FOR IMMUNIZING AGAINST INFLUENZA VIRUS
EP2227249A4 (en) IMPROVED IMMUNIZING COMPOSITION
PL1896065T3 (pl) Sposób wytwarzania szczepionek
BRPI0814941A2 (pt) Composição de tratamentode semente, e, método de tratamento de semente.
DK3309139T3 (da) Process for the preparation of 2,3,3,3-trifluoropropene
DK2077287T3 (da) Fremgangsmåde til fremstilling af blødt polyurethanskum
PL1993985T3 (pl) Sposób wytwarzania 1,2-propanodiolu
BRPI0810270A2 (pt) "implante de válvula cardíaca e método de implante"
EP1888765A4 (en) METHOD AND COMPOSITIONS FOR DIAGNOSIS OF VENOUS THROMBOEMBOLIC ILLNESSES
ATE516817T1 (de) Impfstoffe zur immunisierung gegen helicobacter
BRPI0822079A2 (pt) Método, fluido de tratamento ácido, e, composição
CL2007002727A1 (es) Proceso de preparacion de anastrozol; y compuestos intermediarios.
EP2305292A4 (en) TRANSDERMAL IMMUNIZER OF S / O TYPE
FR2909743B1 (fr) Joint d'etancheite.
PL1853220T5 (pl) Sposób wytwarzania pastylek zawierających NLPZ, ich kompozycje, ich zastosowanie medyczne
EP1904097A4 (en) MALARIA MSP-1 C-TERMINAL REINFORCED SUBUNIT VACCINE
ITMO20060388A1 (it) Metodo per la realizzazione di manufatti fotoluminescenti e manufatto fotoluminescente cosi' ottenibile.
ITMI20051910A1 (it) Metodo per la preparazione di colture batteriche probiotiche anallergiche e relativo impiego
ITMI20062515A1 (it) Procedimento per la preparazione di 3,6-di-o-aceti-d-glicali
ITMI20060489A1 (it) Procedimento per la preparazione di 1-beono-3-trifluorometossibenzene
ITMI20061212A1 (it) Metodo per la preparazione di colture batteriche probiotiche anallergiche e relativo impiego

Legal Events

Date Code Title Description
PLFP Fee payment

Year of fee payment: 10

ST Notification of lapse

Effective date: 20170630